UK agency says Pfizer breast cancer drug too expensive

LONDON (Reuters) - Pfizer's breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain's state-run health service, the country's healthcare cost-effectiveness watchdog said on Friday.

The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials.

"Even when allowing for these potential benefits, it was still not enough to make palbociclib cost effective at its current price," Carole Longson, director of NICE's center for health technology assessment, said in a statement on Friday.

Ibrance's list price is 2,950 pounds ($3,700) per 28 days.

Pfizer UK's oncology head David Montgomery noted that the NICE decision was not final decision and said the U.S. drugmaker was committed to working to try and find a solution to make the drug available.

(Reporting by Ben Hirschler, editing by Pritha Sarkar)

Related News

Philippine mining firms urge minister to publish...

Feb 7, 2017

US-PHILIPPINES-MINING:Philippine mining firms urge minister to publish audit

China, United States cannot afford conflict:...

Feb 7, 2017

US-AUSTRALIA-CHINA-TRUMP:China, United States cannot afford conflict: Chinese foreign minister

Bitcoin hits one-month high after China FX...

Feb 7, 2017

US-GLOBAL-MARKETS-BITCOIN:Bitcoin hits one-month high after China FX reserves fall

China 'mending its ways' on unethical organ...

Feb 8, 2017

US-VATICAN-TRANSPLANTS-CHINA:China 'mending its ways' on unethical organ transplants, official says

Tillerson stresses cooperation in calls with...

Feb 7, 2017

US-USA-ASIA-TILLERSON:Tillerson stresses cooperation in calls with Australia, Japan, South Korea

China says United States should 'brush up on'...

Feb 8, 2017

US-SOUTHCHINASEA-CHINA-USA:China says United States should 'brush up on' South China Sea history

About Us

In the busy city of New York, News On Express fills you in with all the breaking world news, in short, and brief news articles so that you can read them on-the-go.

Contact us: sales[at]newsonexpress.com

Subscribe Now!